Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Endocrine Pathology
Published in: Endocrine Pathology 4/2017

01-12-2017

Long-Term Outcomes of Patients with Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features (NIFTP) ≥4 cm Treated Without Radioactive Iodine

Author: Pedro Weslley Rosario

Published in: Endocrine Pathology | Issue 4/2017

Login to get access

Excerpt

Dear Editor …
Literature
1.
Haugen BR, Sawka AM, Alexander EK et al.: The ATA Guidelines on Management of Thyroid Nodules and Differentiated Thyroid Cancer Task Force Review and Recommendation on the Proposed Renaming of eFVPTC without Invasion to NIFTP. Thyroid 2017, 27:481–483.CrossRefPubMed
2.
Haugen BR, Alexander EK, Bible KC et al.: 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 2016, 26:1–133.
3.
Xu B, Tallini G, Ghossein RA: Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features: Historical Context, Diagnosis, and Future Challenges. Endocr Pathol. 2017, 28:128–138.CrossRefPubMed
4.
Xu B, Tallini G, Scognamiglio T et al.: Outcome of Large Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features (NIFTP). Thyroid 2017, 27:512–517.CrossRefPubMed
5.
Rosario PW, Mourão GF, Nunes MB et al.: Noninvasive Follicular Thyroid Neoplasm With Papillary-Like Nuclear Features. Endocrine Related Cancer 2016, 23:893–897.CrossRefPubMed
Metadata
Title
Long-Term Outcomes of Patients with Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features (NIFTP) ≥4 cm Treated Without Radioactive Iodine
Author
Pedro Weslley Rosario
Publication date
01-12-2017
Publisher
Springer US
Published in
Endocrine Pathology / Issue 4/2017
Print ISSN: 1046-3976
Electronic ISSN: 1559-0097
DOI
https://doi.org/10.1007/s12022-017-9493-4

Other articles of this Issue 4/2017

Endocrine Pathology 4/2017 Go to the issue

Announcement

Endocrine Pathology Society Hubert Wolfe Award for 2017: Call for Nominations

OriginalPaper

A Novel TP53 Mutation Associated with TWIST1 and SIP1 Expression in an Aggressive Adrenocortical Carcinoma

OriginalPaper

Immunoglobulin G4 (IgG4)-Related Hypophysitis

OriginalPaper

Pathological and Genetic Characterization of Bilateral Adrenomedullary Hyperplasia in a Patient with Germline MAX Mutation

OriginalPaper

Depletion of Beta Cell Intranuclear Rodlets in Human Type II Diabetes

ReviewPaper

Hobnail Variant of Papillary Thyroid Carcinoma: a Literature Review
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits